Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
AgeX Therapeutics, Inc. stock logo
AGE
AgeX Therapeutics
$3.89
$11.07
$35.71
$11.99M1.183,849 shs3,700 shs
The Marcus Co. stock logo
MCS
Marcus
$13.47
-1.3%
$14.09
$12.78
$17.84
$427.27M1.47417,706 shs265,746 shs
PSM
Principal U.S. Small-MidCap Multi-Factor ETF
$29.53
$29.53
$15.33
$29.53
$11.81MN/A921 shsN/A
RYO
Rio Silver
C$0.04
+16.7%
C$0.03
C$0.02
C$0.06
C$2.97M2.1450,388 shs1,000 shs
SJL
ProShares UltraShort Russell Mi
$0.00
$60.25
$91.75
N/AN/AN/A164,250 shs
These 7 Stocks Will Be Magnificent in 2024 Cover

With average gains of 150% since the start of 2023, now is the time to give these stocks a look and pump up your 2024 portfolio.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
AgeX Therapeutics, Inc. stock logo
AGE
AgeX Therapeutics
0.00%0.00%-11.90%+4,340.00%+2,632.31%
The Marcus Co. stock logo
MCS
Marcus
+0.66%+6.31%-3.16%+0.81%-20.33%
PSM
Principal U.S. Small-MidCap Multi-Factor ETF
0.00%0.00%0.00%0.00%0.00%
RYO
Rio Silver
-33.33%-14.29%+20.00%0.00%0.00%
SJL
ProShares UltraShort Russell Mi
0.00%0.00%0.00%0.00%0.00%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
AgeX Therapeutics, Inc. stock logo
AGE
AgeX Therapeutics
N/AN/AN/AN/AN/AN/AN/AN/A
The Marcus Co. stock logo
MCS
Marcus
4.6061 of 5 stars
3.51.01.73.31.91.73.1
PSM
Principal U.S. Small-MidCap Multi-Factor ETF
N/AN/AN/AN/AN/AN/AN/AN/A
RYO
Rio Silver
N/AN/AN/AN/AN/AN/AN/AN/A
SJL
ProShares UltraShort Russell Mi
N/AN/AN/AN/AN/AN/AN/AN/A

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
AgeX Therapeutics, Inc. stock logo
AGE
AgeX Therapeutics
N/AN/AN/AN/A
The Marcus Co. stock logo
MCS
Marcus
3.00
Buy$19.6746.00% Upside
PSM
Principal U.S. Small-MidCap Multi-Factor ETF
0.00
N/AN/AN/A
RYO
Rio Silver
N/AN/AN/AN/A
SJL
ProShares UltraShort Russell Mi
N/AN/AN/AN/A

Current Analyst Ratings

Latest SJL, PSM, RYO, AGE, and MCS Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
4/22/2024
The Marcus Co. stock logo
MCS
Marcus
Barrington Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform ➝ Outperform$20.00 ➝ $20.00
3/5/2024
The Marcus Co. stock logo
MCS
Marcus
Benchmark
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$20.00
3/1/2024
The Marcus Co. stock logo
MCS
Marcus
Barrington Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform ➝ Outperform$20.00
(Data available from 4/25/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
AgeX Therapeutics, Inc. stock logo
AGE
AgeX Therapeutics
$140K0.00N/AN/A($16.07) per share0.00
The Marcus Co. stock logo
MCS
Marcus
$729.58M0.59$2.62 per share5.14$14.85 per share0.91
PSM
Principal U.S. Small-MidCap Multi-Factor ETF
N/AN/AN/AN/AN/AN/A
RYO
Rio Silver
N/AN/AC$0.00 per share30.00C($0.01) per shareN/A
SJL
ProShares UltraShort Russell Mi
N/AN/AN/AN/AN/AN/A

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
AgeX Therapeutics, Inc. stock logo
AGE
AgeX Therapeutics
-$14.80M-$13.03N/AN/AN/A-10,424.65%N/A-120.90%5/13/2024 (Estimated)
The Marcus Co. stock logo
MCS
Marcus
$14.79M$0.3143.4527.4912.902.03%3.19%1.40%5/2/2024 (Confirmed)
PSM
Principal U.S. Small-MidCap Multi-Factor ETF
N/AN/A0.00N/AN/AN/AN/AN/A
RYO
Rio Silver
N/A-C$0.01N/AN/AN/AN/A-401.21%N/A
SJL
ProShares UltraShort Russell Mi
N/AN/A0.00N/AN/AN/AN/AN/AN/A

Latest SJL, PSM, RYO, AGE, and MCS Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/2/2024N/A
The Marcus Co. stock logo
MCS
Marcus
-$0.41N/A+$0.41N/AN/AN/A  
2/29/2024Q4 2023
The Marcus Co. stock logo
MCS
Marcus
-$0.17-$0.05+$0.12-$0.05$160.75 million$161.53 million

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
AgeX Therapeutics, Inc. stock logo
AGE
AgeX Therapeutics
N/AN/AN/AN/AN/A
The Marcus Co. stock logo
MCS
Marcus
$0.282.08%+12.18%90.32%1 Years
PSM
Principal U.S. Small-MidCap Multi-Factor ETF
$0.431.46%N/AN/AN/A
RYO
Rio Silver
N/AN/AN/AN/AN/A
SJL
ProShares UltraShort Russell Mi
N/AN/AN/AN/AN/A

Latest SJL, PSM, RYO, AGE, and MCS Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
2/22/2024
The Marcus Co. stock logo
MCS
Marcus
quarterly$0.071.9%3/1/20243/4/20243/15/2024
(Data available from 1/1/2013 forward)

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
AgeX Therapeutics, Inc. stock logo
AGE
AgeX Therapeutics
N/A
0.13
0.36
The Marcus Co. stock logo
MCS
Marcus
0.37
0.62
0.62
PSM
Principal U.S. Small-MidCap Multi-Factor ETF
N/AN/AN/A
RYO
Rio Silver
N/A
0.07
0.06
SJL
ProShares UltraShort Russell Mi
N/AN/AN/A

Ownership

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
AgeX Therapeutics, Inc. stock logo
AGE
AgeX Therapeutics
51.08 million1.01 millionNot Optionable
The Marcus Co. stock logo
MCS
Marcus
7,78031.72 million30.14 millionOptionable
PSM
Principal U.S. Small-MidCap Multi-Factor ETF
N/A400,000N/ANot Optionable
RYO
Rio Silver
N/A84.83 millionN/ANot Optionable
SJL
ProShares UltraShort Russell Mi
N/AN/AN/ANot Optionable

SJL, PSM, RYO, AGE, and MCS Headlines

SourceHeadline
Jonathan M. RussellJonathan M. Russell
health.usnews.com - February 4 at 12:26 AM
When the Price of Proshares Ultrashort Russell20 $TWM Talks, People ListenWhen the Price of Proshares Ultrashort Russell20 $TWM Talks, People Listen
marketwatch.com - April 21 at 1:30 AM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

All Headlines

Company Descriptions

AgeX Therapeutics logo

AgeX Therapeutics

NYSE:AGE
AgeX Therapeutics, Inc., a biotechnology company, focuses on the development and commercialization of novel therapeutics targeting human aging and degenerative diseases in the United States. The company's lead cell-based therapeutic candidates in development include AGEX-BAT1, a cell therapy product candidate for the treatment of various age-related metabolic disorders, such as Type II adult-onset diabetes and obesity; and AGEX-VASC1, a cell-based therapy to restore vascular support in aged ischemic tissues, such as peripheral vascular disease and ischemic heart disease. Its lead small molecule drug-based therapeutic candidate for scarless wound repair in discovery is AGEX-iTR1547, a drug-based formulation; and lead biologic candidate for induced tissue regeneration is AGEX-iTR1550 (Renelon), a gene delivery technology. AgeX Therapeutics, Inc. has a research collaboration with the University of California at Irvine to develop cellular therapies to treat neurological disorders and diseases. The company was incorporated in 2017 and is based in Alameda, California.
Marcus logo

Marcus

NYSE:MCS
The Marcus Corporation, together with its subsidiaries, owns and operates movie theatres, and hotels and resorts in the United States. It operates a family entertainment center and multiscreen motion picture theatres under the Big Screen Bistro, Big Screen Bistro Express, BistroPlex, and Movie Tavern by Marcus brand names. The company also owns and operates full-service hotels and resorts, as well as manages full-service hotels, resorts, and other properties. In addition, it provides hospitality management services, including check-in, housekeeping, and maintenance for a vacation ownership development; and manages condominium hotels under long-term management contracts. The Marcus Corporation was founded in 1935 and is headquartered in Milwaukee, Wisconsin.

Principal U.S. Small-MidCap Multi-Factor ETF

NASDAQ:PSM

Rio Silver

CVE:RYO
Rio Silver Inc. engages in the acquisition, evaluation, and development of mineral properties in the Americas, Canada, and Peru. It explores for precious and base metal deposits. The company owns 100% interest in Niñobamba silver and gold project covering an area of 4,490 hectares located in the Department of Ayacucho, Peru. It also holds 100% interest in the Gerow Lake property, a base metal project located in northwestern Ontario, Canada; and holds 100% interest in Palpa Dorado property covering an area of 1,200 hectares located in Moro district of Santa province, Ancash, Peru. The company was formerly known as Escape Gold Inc. and changed its name to Rio Silver Inc. in October 2011. Rio Silver Inc. is based in Vancouver, Canada.

ProShares UltraShort Russell Mi

NYSEARCA:SJL
ProShares UltraShort Russell MidCap Value (the Fund) seeks daily investment results that correspond to twice the inverse daily performance of the Russell MidCap Value Index. The Russell MidCap Value Index measures the performance of the mid-capitalization value sector of the United States equity market. The Index represents approximately 52% of the total market capitalization of the Russell Midcap Index. The Index is a capitalization-weighted index and consists of those companies with lower price-to-book ratios within the Russell Midcap Index. The Fund intends to invest at least 80% of its net assets, including any borrowings for investment purposes, to investments that, in combination, have economic characteristics that are inverse to those of the Index. The Fund intends to concentrate its investments in a particular industry or group of industries to approximately the same extent as the Index is so concentrated. ProShare Advisors LLC serves as the investment advisor to the Fund.